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ABSTRACT: Polypharmacology is often a key contributor to the efficacy of a drug, but is also a potential risk. We investigated 
two hits discovered via a cell-based phenotypic screen, the CDK9 inhibitor CCT250006 1 and the pirin ligand CCT245232 2, to 
establish methodology to elucidate their secondary protein targets. Using computational pocket-based analysis, we discovered intra-
family polypharmacology for our kinase inhibitor, despite little overall sequence identity. The inter-family polypharmacology of 2 
with B-Raf was used to discover a novel pirin ligand from a very small but privileged compound library, despite no apparent ligand 
or binding site similarity. Our data demonstrates that in areas of drug discovery where intra-family polypharmacology is often an 
issue, ligand dissimilarity cannot necessarily be used to assume different off-target profiles and that understanding inter-family 
polypharmacology will be important in the future to reduce the risk of idiopathic toxicity and in the design of screening libraries.
Polypharmacology, where small molecules bind to more 
than one protein target at concentrations relevant to their 
therapeutic free exposure,1,2 is a key element in drug discovery 
and development. It can be beneficial as an essential part of 
the efficacy and phenotype of a drug, particularly in complex 
diseases such as cancer,3 but can also be detrimental, leading 
to toxicity by hitting undesirable protein targets.4 This balance 
in therapeutic index can represent a significant challenge in 
lead optimization.5
Privileged structures are defined as small molecule scaffolds 
that are able to bind more than one receptor,6 a concept which 
has been useful in compound library design and in 
understanding polypharmacology.7
We recognized that there are four types of 
polypharmacology that are directly relevant to drug discovery. 
i) The first is often encountered in small molecule probes used 
in chemical biology, for example PROTACs,8 and in the 
rational design of dual inhibitors, such as the combination of 
histone deacetylase (HDAC) inhibitors with janus kinase9 and 
IDO1-targeting compounds.10 In this approach, two distinct 
compounds, usually with different functions and selectivities, 
are attached to each other via a flexible linker, with the aim 
that despite being attached, each motif of the chemical probe 
will retain its activity.
ii) The second is described by weak and often non-specific 
interactions with proteins outside of the target protein’s 
family.11 These anti-targets are broadly characterized in in 
vitro safety pharmacology screens,12 where binding to 
promiscuous targets can cause adverse drug reactions at high 
dose; for example, adenosine A2a receptor and hERG.
iii) Owing to high sequence similarity in the active sites 
within a protein family, small molecule ligands often bind 
with high affinity to multiple members of that family.13,14 This 
type of polypharmacology is particularly well established in 
kinase drug discovery,15 where privileged structures of certain 
hinge-binding motifs display low selectivity within the 
family,16 an effect that can lead to a poor therapeutic index 
(staurosporin)17 or be crucial for efficacy (aurora/FLT3).18
iv) The final type of polypharmacology that can impact drug 
discovery has only recently been recognized,19 largely due to 
broad proteome screening platforms becoming readily 
available. High affinity specific interactions can occur for 
ligands binding to different protein families, despite no 
apparent binding site or sequence similarity.20,21 This concept 
was recently highlighted by the discovery that the well 
characterized potent kinase inhibitor, BI-2536 (PLK1, 
IC50=0.83 nM),22 binds with high affinity to the bromodomain 
family protein, BRD4 (IC50=25-37 nM). However, it is unclear 
whether the inter-family activity encountered represents an 
inherent conservation in protein structure, expressed through 
an underlying similarity between protein binding sites, or is 
simply an anomaly.
We recently carried out a cell-based high-throughput 
phenotypic screen to discover inhibitors of the heat shock 
transcription factor 1 (HSF1) stress pathway.23 From the 
screen, we identified two novel series and exploited several 
molecular target identification strategies to discover direct 
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protein targets for each chemotype. The first series, 
exemplified by aminopyrimidine CCT250006 1 (Figure 1C), 
proved to bind with high affinity to the RNA polymerase II 
regulator, cyclin-dependent kinase 9 (CDK9, IC50≤3.0 nM).24 
The second series, exemplified by bisamide CCT245232 2 
(Table 2, Entry 1), bound with high affinity to the putative 
transcription factor regulator, pirin (SPR KD=38 nM).23 As 
these compounds were discovered via a phenotypic screen, 
which did not discriminate against mechanisms of action 
(MOA) derived from the inhibition of multiple protein 
targets,25,26 we were interested in determining what role 
polypharmacology could play in both the efficacy and 
potential toxicity of these chemotypes.
We began our investigation into polypharmacology by 
exploring the well-established promiscuity of ATP-
competitive kinase inhibitors. This was accomplished through 
binding site analysis to assess the pocket similarity of CDK9 
with various other kinases using the pocket comparison tool, 
SiteHopper, to rank and select proteins for further analysis.27,28 
The SiteHopper tool represents pockets as 3D patches encoded 
with spatial information concerning the local molecular 
surface (shape) and chemical properties (color) of residues 
lining protein binding sites. Binding site patches are aligned 
and their overlap scored, yielding a continuous PatchScore 
between zero and four, conveying dissimilarity and perfect 
similarity, respectively. Binding sites were identified using the 
fpocket cavity detection tool,29 enabling the use of homology 
models and unbound protein structures in the analysis30 (see 
pocket analysis section in SI for details). To narrow the search 
space, we retrieved the off-target kinase profile of the well-
validated CDK9 inhibitor dinaciclib 3 (Figure 1C).31 The 1,5-
pyrazolopyrimidine structure of dinaciclib 3 is a distinct 
chemotype from our aminopyrimidine inhibitor 1, when 
compared using their ECFC_4 molecular fingerprint Tanimoto 
coefficients (TC=0.41).32 We hypothesized that as there was 
limited structural similarity between the potent CDK9 ligands, 
then any cross-selectivity with other protein kinases may 
manifest as similarity in the respective small molecule binding 
sites. The kinase profile of dinaciclib 3 was obtained from the 
publicly available HMS LINCS database (456 kinase targets)33 
and we only considered kinases that exhibited less than a 5% 
difference in response compared to CDK9. This analysis left 
30 distinct kinases, of which, 21 could be assessed for binding 
site similarity due to the availability of structural data. We 
retrieved structures from both the Protein Data Bank (PDB) 
and, where available, homology models from the Protein 
Model Portal (PMP),34 giving a total of 252 protein structures 
(Table S1).
The SiteHopper pocket analysis tool was then applied to our 
21 kinase dataset, comparing detected pockets of each kinase 
with reference pockets derived from structures of CDK9. Each 
kinase was analyzed with respect to the maximum PatchScore 
observed with any of the reference CDK9 pockets. This 
analysis identified 11 kinases with a maximum PatchScore of 
greater than 1.3 (Tables 1 and S2), a cut-off proposed to 
describe significant structural similarity between binding 
sites.27 As expected, CDK9 itself was the top-ranked hit, as the 
score simply represents conformation differences between 
different protein structures. The second ranked hit, CDK2 and 
CDK14, had already been confirmed as a direct protein target 
of 1 from our previous work.24 From the remaining hits, 
TAOK1 and HIPK2 (discovered from analysis of homology 
models) were selected for further study as they were 
evolutionarily more distant from CDK9, with sequence 
identities of 24% and 8%, and sequence homology of 48% and 
40%, respectively, and for which functional assays were 
available. The activity of aminopyrimidine 1 was assessed 
using radio labelled filter binding assays, to give IC50 values of 
490 nM and 30 nM for TAOK1 and HIPK2, respectively 
(Tables S4 and S5).35 Therefore, despite little total sequence 
identity between TAOK1, HIPK2 and CDK9, each protein still 
shares a common kinase fold and possesses similar binding 
sites, resulting in intra-family polypharmacology (Figure 1A, 
1B, S3 and S4).
Although from these data we cannot conclude that either 
kinase will significantly contribute to the efficacy or in vivo 
toxicology of aminopyrimidine 1, they do suggest that binding 
site pocket analysis can be a useful tool for prioritizing off-
target proteins for further evaluation as part of a lead 
optimization selectivity assessment. Particularly as neither 
protein kinase selected using pocket analysis displays high 
sequence similarity to CDK9,36 so may not have been chosen 
Figure 1. Rational Polypharmacology within the Kinase Family. A: A close analogue of aminopyrimidine 1 bound to CDK2 (PDB: 4BZD, 
green) and overlaid with CDK9 (PDB: 4EC8, turquoise) and homology models of TAOK1 (brown) and HIPK2 (yellow); despite little 
overall sequence identity, the proteins show clear pocket shape similarity, which was detected by the pocket analysis tool. C=grey, N=blue, 
O=red, H and solvent omitted for clarity. B: Key interactions of the close analogue of 1 with CDK2 (PDB: 4BZD, green), compared to the 
equivalent residues in CDK9 (blue), TAOK1 (brown) and HIPK2 (yellow), showing that these key residues are retained. C: Chemical 
structure of aminopyrimidine 1 and the well validated CDK9 inhibitor dinaciclib 3.
Table 1. SiteHopper Analysis comparing the Kinase 
Binding Site Similarity with CDK9
Only the top 11 hits are shown using the maximum score 
obtained against all available conformations, see the SI for details.
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for further study based on this commonly used selectivity 
criterion. Our data demonstrates that in areas of drug 
discovery where intra-family polypharmacology is often an 
issue, ligand dissimilarity cannot necessarily be used to 
assume different off-target profiles. Additionally, our analysis 
makes use of publicly available homology models retrieved 
from the PMP. Caution must always be exercised when 
considering these data, but as pocket comparison using 
SiteHopper does not involve precise modelling of directional 
interactions between proteins and ligands, homology models 
can be valuable. This allows proteins to be studied for 
polypharmacology, even when structures are not yet available. 
Although we were successful in using pocket analysis to 
discover off-target proteins from within the kinase family with 
the pyrimidine series, identifying additional high affinity 
targets for the second bisamide series proved to be more 
challenging. Pirin is a member of the cupin superfamily of 
proteins,37 defined by the beta-barrel structure at their center. 
Members of the cupin super family possess little sequence 
similarity and display a wide range of both catalytic and non-
catalytic functions.38 In contrast to our CDK9 example of 
polypharmacology, all binding site and pocket analysis tools, 
as well as sequence similarity searching, yielded no protein 
hits for further investigation (data not shown). 
Using in vitro kinase recombinant protein profiling, we had 
previously shown that bisamide 2 possessed moderate affinity 
for the protein kinase, B-Raf (IC50=420 nM), concurrent with 
its high affinity for pirin (KD=38 nM).23 The inter-family 
protein activity of bisamide 2 for both B-Raf and pirin is 
surprising, as the two proteins possess no significant binding 
site sequence similarity. To rationalize this result, we solved 
the crystal structure of bisamide 2 bound to pirin (Figure 2A, 
S8, S14 and Table S6) and compared its binding mode to the 
docked structure of bisamide 2 in B-Raf (Figure 2B). 
Bisamide 2 displays a distinct binding conformation in pirin, 
with the two amide carbonyls forming an eclipsed 
conformation around the central ring. In the docked structure 
of bisamide 2 in B-Raf, assumed to be ATP competitive, the 
two amide carbonyls form a perpendicular conformation, 
consistent with the crystal structures of the bisamide 
chemotype bound to EphA3 (PDB: 3DZQ) and p38 (PDB: 
3KQ7) kinases (Figures S5 and S6). This is in contrast to the 
BRD4/PLK1 example of inter-family polypharmacology,20 
where BI-2536 adopts essentially an identical conformation 
against both protein targets (Figure S7).
Even though pocket analysis had been unable to detect any 
similarity between the pirin and B-Raf binding sites, we 
hypothesized that if the affinity of bisamide 2 to both proteins 
was a more general phenomenon, then it should be possible to 
Table 2. Inter-Family Polypharmacology Screen of Pirin and B-Raf
ND=Not determined aAll compounds were purchased from Selleckchem (www.selleckchem.com accessed June 2016). bCompared to 
the dual pirin/B-Raf ligand bisamide 2, calculated using ECFC_4 molecular fingerprint Tanimoto coefficients as implemented in Pipeline 
Pilot v9.5. cFor references of the described B-Raf activities, see the SI. dMeasured using the pirin FP-assay and represents the geometric 
mean of at least n=2 repeats. 
Entry Compd Structurea Name Similarity(ECFC_4 TC)b
B-Raf (WT/V600E)
IC50 (M)c
Pirin
IC50 (M)d
1 2 CCT245232 NA 0.42/0.21 0.044
2 5 CCT251236 0.88 2.9/ND 0.033
3 6 CCT273166 0.88 ND/ND >10
4 7 PLX4720 0.38 0.160/0.013 0.67
5 8 CCT363294 0.82 >10/ND 0.033
6 9 Vemurafenib 0.54 0.10/0.031 >10
7 10 AZ268 0.67 ND/<0.001 >10
8 11 TAK-632 0.55 0.008/0.002 >10
9 12 RAF265 0.50 ND/0.020 >10
10 13 Dabrafenib 0.49 0.005/<0.001 >10
11 14 GDC-0879 0.44 ND/<0.001 >10
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discover a second ligand of a distinct chemotype that could 
bind to both proteins. 
The bisamides are currently the only known high affinity 
chemotype for pirin but B-Raf has been extensively studied,39 
resulting in multiple inhibitors of distinct chemotype being 
discovered. To rapidly screen B-Raf inhibitors in an efficient 
manner, we developed a new pirin binding assay. 
Fluorescence polarization (FP) assays are highly versatile and 
have been widely used to characterize proteins that do not 
possess enzymatic activity.40 The design of the FP-probe was 
carried out by analysis of the crystal structure of 2 bound to 
recombinant pirin, and through strong precedent from previous 
pirin ligand design (Figures 2B, 2G and S13),23,42 The FP-
probe 4 (Figure 2G) was synthesized using a 9-atom linker in 
7 steps and 1.2% overall yield (see Chemistry Experimental 
section in SI).
Titration of recombinant pirin against a fixed concentration 
(2.0 nM) of FP-probe 4 revealed a very high apparent affinity 
for pirin (KD=11 nM), within 5-fold of the FP-probe 4 
concentration (Figure S1). Using the FP-assay, bisamide 2 and 
our pirin chemical probe CCT251236 541 gave IC50 values of 
44 nM (pIC50=7.36±0.10, n=4) and 33 nM (pIC50=7.48±0.09, 
n=46), respectively, at the tight-binding limit of the assay (for 
an example see Figure S2). Our negative control regioisomer 6 
failed to displace the FP-probe 4 at concentrations greater than 
1 M. These results were comparable to our previous surface 
plasmon resonance (SPR) data for pirin.23
A panel of seven well-validated and potent B-Raf inhibitors 
(Entries 4 and 6-11 in Table 2),43 representing several 
chemotypes distinct from bisamide 2 (TC=0.38-0.67), were 
purchased and screened in the pirin FP-assay. No activity was 
observed against pirin with six of the B-Raf inhibitors. 
However, when we screened the ligand with the lowest TC 
compared to bisamide 2, the azaindole derived inhibitor, 
PLX4720 7, the ligand demonstrated a high affinity for pirin 
(IC50=0.67 M, Table 2, Entry 4). Therefore, despite sharing 
little chemical similarity to bisamide 2, PLX4720 7 was also 
able bind both pirin and B-Raf, representing a 14% hit-rate 
from our very small privileged compound library.
To rationalize the high affinity of PLX4720 7 for pirin, we 
solved its crystal structure (Figures 2C, S10, S16, and Table 
S6) and compared it to bisamide 2 (Figure S12). PLX4720 7, 
like bisamide 2, forms no direct interactions with the metal-
center of pirin, instead forming hydrogen bonds through the 
metal-bound water molecule and the central ketone carbonyl. 
The NH-group of the azaindole moiety acts as a hydrogen 
bond donor with Asp43, in a similar manner to the methyl-
distal amide of bisamide 2. The remaining portion of the 
azaindole ring forms a -stacking interaction with Phe53 and 
points deeply into the lipophilic narrow binding tunnel, 
leaving the propyl-sulfonamide moiety essentially solvent 
exposed and highly flexible as it could not be observed in the 
electron density. This is in contrast to the binding mode of 
PLX4720 7 bound to B-Raf (Figure 2D, PDB: 3C4C), where 
the propyl-sulfonamide moiety is now buried deeply within a 
lipophilic region of the protein and it is the azaindole motif 
which points towards the solvent channel. 
The dissimilarity in binding mode demonstrates that 
although our two privileged ligands (2 and 7) could bind 
proteins across families with high affinity, their structure-
activity relationships (SAR) towards each target remain 
essentially distinct. Against pirin, we could exploit the 
Figure 2. Structural Comparison of Pirin and B-Raf. N=blue, O=red, S=yellow, Cl=green, Metal=brown, H omitted for clarity. Only key 
residues have been shown and the solvent, except the metal-bound water, has been omitted for clarity. Hydrogen bonds are shown as 
yellow dashes. A: Bisamide 2 bound to pirin demonstrating the key hydrogen bonds to Asp43 and the metal-bound water, and the amide-
eclipsed conformation. The quinoline ring motif is solvent exposed. B: Docked structure of bisamide 2 bound to B-Raf (PDB: 4G9C, see 
Figures S4 and S5 for additional pictures), 2 binds in a distinct staggered conformation and the quinoline ring motif is placed in close 
proximity to the hinge region. C: Structure of PLX4720 7 bound to pirin. The azaindole-ketone motif forms an equivalent hydrogen 
bonding array to the amide of 2. The chloro-substituent is buried deeply within the narrow binding tunnel. Because the sulfonamide moiety 
is disordered it cannot be observed in the electron density but is shown here for clarity. D: PLX4720 7 bound to B-Raf (PDB: 3C4C). The 
azaindole motif interacts with the hinge region and the chloro-substituent points on a solvent exposed vector. E and F: Key interaction of 
PLX4720 7 and bisamide 2, respectively, bound to pirin. Hydrogen bonds are represented by an arrow, pi-stacking interactions by a dotted 
line. Key interactions of both ligands bound to B-Raf are shown in Figure S14. G: Chemical structure of FP-Probe 4.
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solvent-exposed quinoline region of bisamide 2 to substitute 
the methylene group with a larger substituent. The t-butyl-
piperazine bisamide analogue 8 retains its high affinity for 
pirin (Table 2, Entry 5) but the piperazine moiety is predicted 
to be in close proximity to the hinge region of B-Raf, where 
bulky substituents should not be tolerated. This orthogonal 
SAR was confirmed when the B-Raf polypharmacology was 
lost in the case of 8 (IC50>10 M). A similar contrast in SAR 
is observed for PLX4720 7. Against B-Raf, the chloro-
substituent is on an essentially solvent-exposed vector and can 
be readily substituted with a phenyl ring, which gives the high 
affinity B-Raf ligand, vemurafinib 9 (Table 2, Entry 6). 
However, against pirin, the chloro-substituent of 7 is buried in 
the lipophilic tunnel, so the phenyl substitution in 9 now 
results in a clear clash with the protein and the complete loss 
of the pirin polypharmacology, enhancing the selectivity for 
B-Raf.44
Understanding the role of polypharmacology in drug 
discovery is essential to improve the efficiency of compound 
development and decrease drug attrition. Using two 
chemotypes discovered from a high-throughput phenotypic 
screen, we have demonstrated that binding site pocket 
similarity analysis can be a useful tool in selecting off-target 
proteins from within the same family for further investigation. 
This approach could offer clear benefits in lead optimization, 
prioritizing the study of secondary targets for their importance 
in efficacy or toxicity. However, when searching for proteins 
outside of the family of the target protein, pocket analysis was 
not predictive. We could demonstrate that, despite there being 
no detectable sequence or shape similarity in the binding sites 
of pirin and B-Raf, there is “inherent” or “underlying” 
similarity between these proteins, resulting in inter-family 
polypharmacology and limited SAR homology45 from two 
distinct chemotypes. Consistent with the BRD4/PLK1 
example, there are no computational methods we are currently 
aware of that are able to detect, quantify or predict this 
phenomenon. An analysis by Shoichet et al. of ligands that 
bound more than one protein from different families46 found 
that the majority of examples of inter-family 
polypharmacology were not as a result of matched residues in 
the ligand binding site and there was no simple code for ligand 
recognition. Nonetheless, using a bottom-up approach, we 
discovered a novel pirin ligand after screening a very small 
privileged compound library. 
As more examples of inter-family polypharmacology 
become available, we will be able to better analyze and 
understand what factors control the underlying similarity in 
protein binding sites and the conservative evolution that nature 
has used to generate them. We will then be better able to 
predict efficacy and idiopathic toxicities before compounds 
reach the clinic and design more efficient high-throughput 
screening libraries of privileged structures possessing the 
appropriate complexity so that they are likely to hit targets 
across the proteome.
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 Figure 1. Rational Polypharmacology within the Kinase Family. A: A close analogue of aminopyrimidine 1 
bound to CDK2 (PDB: 4BZD, green) and overlaid with CDK9 (PDB: 4EC8, turquoise) and homology models 
of TAOK1 (brown) and HIPK2 (yellow); despite little overall sequence identity, the proteins show clear 
pocket shape similarity, which was detected by the pocket analysis tool. C=grey, N=blue, O=red, H and 
solvent omitted for clarity. B: Key interactions of the close analogue of 1 with CDK2 (PDB: 4BZD, green), 
compared to the equivalent residues in CDK9 (blue), TAOK1 (brown) and HIPK2 (yellow), showing that 
these key residues are retained. C: Chemical structure of aminopyrimidine 1 and the well validated CDK9 
inhibitor dinaciclib 3. 
1080x245mm (96 x 96 DPI) 
Page 8 of 12
ACS Paragon Plus Environment
ACS Medicinal Chemistry Letters
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
 SiteHopper Analysis comparing the Kinase Binding Site Similarity with CDK9 
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 Structural Comparison of Pirin and B-Raf. N=blue, O=red, S=yellow, Cl=green, Metal=brown, H omitted for 
clarity. Only key residues have been shown and the solvent, except the metal-bound water, has been 
omitted for clarity. Hydrogen bonds are shown as yellow dashes. A: Bisamide 2 bound to pirin 
demonstrating the key hydrogen bonds to Asp43 and the metal-bound water, and the amide-eclipsed 
conformation. The quinoline ring motif is solvent exposed. B: Docked structure of bisamide 2 bound to B-Raf 
(PDB: 4G9C, see Figures S4 and S5 for additional pictures), 2 binds in a distinct staggered conformation and 
the quinoline ring motif is placed in close proximity to the hinge region. C: Structure of PLX4720 7 bound to 
pirin. The azaindole-ketone motif forms an equivalent hydrogen bonding array to the amide of 2. The chloro-
substituent is buried deeply within the narrow binding tunnel. Because the sulfonamide moiety is disordered 
it cannot be observed in the electron density but is shown here for clarity. D: PLX4720 7 bound to B-Raf 
(PDB: 3C4C). The azaindole motif interacts with the hinge region and the chloro-substituent points on a 
solvent exposed vector. E and F: Key interaction of PLX4720 7 and bisamide 2, respectively, bound to pirin. 
Hydrogen bonds are represented by an arrow, pi-stacking interactions by a dotted line. Key interactions of 
both ligands bound to B-Raf are shown in Figure S14. G: Chemical structure of FP-Probe 4. 
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